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Abstract
Background: Higher fish or higher docosahexaenoic acid (DHA) intake normally correlates positively with higher
plasma DHA level, but recent evidence suggests that the positive relationship between intake and plasma levels of
DHA is less clear in the elderly.
Methods: We compared the metabolism of
13C-DHA in six healthy elderly (mean - 77 y old) and six young adults
(mean - 27 y old). All participants were given a single oral dose of 50 mg of uniformly labelled
13C-DHA. Tracer
incorporation into fatty acids of plasma triglycerides, free fatty acids, cholesteryl esters and phospholipids, as well
as apparent retroconversion and b-oxidation of
13C-DHA were evaluated 4 h, 24 h, 7d and 28d later.
Results: Plasma incorporation and b-oxidation of
13C-DHA reached a maximum within 4 h in both groups, but
13C-DHA was transiently higher in all plasma lipids of the elderly 4 h to 28d later. At 4 h post-dose,
13C-DHA
b-oxidation was 1.9 times higher in the elderly, but over 7d, cumulative b-oxidation of
13C-DHA was not different
in the two groups (35% in the elderly and 38% in the young). Apparent retroconversion of
13C-DHA was well
below 10% of
13C-DHA recovered in plasma at all time points, and was 2.1 times higher in the elderly 24 h and 7d
after tracer intake.
Conclusions: We conclude that
13C-DHA metabolism changes significantly during healthy aging. Since DHA is a
potentially important molecule in neuro-protection, these changes may be relevant to the higher vulnerability of
the elderly to cognitive decline.
Background
The consumption of fish containing eicosapentaenoic
(EPA) and docosahexaenoic (DHA) acids protects
against cardiovascular disease risk [1] and is possibly
associated with lower risk of cognitive decline [2,3].
Higher fish or higher EPA and DHA intake normally
correlates positively with higher plasma EPA and DHA
levels [4], but recent evidence suggests that the positive
relationship between intake and plasma levels of EPA
and DHA is less clear in the elderly [5-9]. For instance,
EPA was 50 - 100% higher in plasma phospholipids (PL)
and total lipids of the elderly than in young adults
consuming the same EPA-enriched supplement [6-8].
Similarly, a DHA-enriched supplement increased DHA
42% more in plasma total lipids in healthy elderly com-
pared to young adults [9]. Higher EPA and DHA con-
centrations is also reported in erythrocyte lipids of the
elderly [10]. Several prospective epidemiological studies
report that higher erythrocyte omega-3 fatty acids is
associated with better cognitive function [11] or with
lower risk of cognitive decline [12-16] in later life.
In the elderly, increased concentrations of omega-3
fatty acid in plasma significantly predict less cognitive
decline over 3 years [17]. Unlike saturated and monoun-
saturated fatty acids, synthesis of DHA from its omega-3
precursor, alpha-linolenic acid, is extremely limited in
humans [18]. Thus, it is recommended that DHA be
obtained from dietary sources. DHA is a potential key
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ponent of synaptic membranes and is involved in mem-
brane repair and fluidity, cell signalling, initiation of
anti-inflammatory processes and gene expression
[19-22].
Tracing metabolism of carbon 13 (
13C)-DHA may
provide useful information about age-related changes in
DHA metabolism in humans [23-25]. In young adults
g i v e na no r a ld o s eo f2 5 0-2 8 0m g
13C-DHA,
13C
enrichment peaked at 2 h post-dose in plasma triglycer-
ides (TG) when the tracer was given in the TG form,
but at 6 h post-dose when esterified to phosphatidylcho-
line [24,25]. Brossard et al. also reported 1.4% apparent
retroconversion of
13C-DHA to
13C-docosapentaenoate
(
13C-DPA) and
13C-EPA 3 d after giving the tracer [24].
Neither the impact of aging on
13C-DHA metabolism
nor b-oxidation of
13C-DHA has yet been investigated
in humans but both may influence the somewhat higher
blood EPA and DHA commonly seen in the healthy
elderly [5-10]. Hence, our aim here was to evaluate the
incorporation of
13C-DHA into plasma lipids, its appar-
ent retroconversion to DPA and EPA, and its b-oxidation
in a group of young adults ~27 y old versus a group of
healthy elderly ~77 y old.
Methods
All procedures reported here were approved by the
Human Ethics Research Committee of the Health and
Social Sciences Center – Sherbrooke University Geria-
trics Institute, which is the committee mandated to
oversee human experimentation at our institution. All
study participants gave informed written consent.
13C-DHA tracer study
Six young participants and six elderly were recruited
(Table 1). All participants were non-smokers, were not
pregnant or lactating, not using medication to control
diabetes, liver disease, renal disease, hypertension, ane-
mia or low serum albumin and had no other clinical evi-
dence of malnutrition. An upper limit of 3.0% DHA in
plasma total lipids was set to exclude those individuals
who were probably already consuming fish oil supple-
ments providing EPA and DHA or who were habitually
eating relatively high amounts of fish. The participants’
medical histories were taken by a registered nurse.
The
13C tracer used in this study was non-radioactive,
safe for human research, uniformly labelled ( > 98%),
and of high chemical purity [26]. At a breakfast sched-
uled in the Metabolic Unit of the Research Center on
Aging, all participants received a muffin and a yogurt
into which we added a single 50 mg dose of
13C-DHA
as the methyl ester. The macronutrient composition of
the 360 kCal muffin was: 13 g of fat containing 2 g satu-
rated fat, 4.8 g of protein, 58.5 g of carbohydrates, 2.8 g
of fibre and 28.9 g of sugar. Complete fatty acid profile
of the muffin was not performed at the time of the
experiment. The composition of the yogurt was 0 g of
fat, 4 g of protein, 5.5 g of carbohydrates and 4.5 g of
sugar for a total of 37.5 kCal. The composition of
200 mL orange juice provided 100 kCal, 1 g of protein,
23 g of carbohydrates and 20 g of sugar. The breakfast
was consumed by all participants within 15 minutes
after giving the tracer.
To follow appearance of
13CO2 coming from
13C-DHA b-oxidation, breath samples were collected at
baseline and 4 h, 24 h and 7d after the tracer was con-
sumed. To collect the breath samples, the participants
breathed in a purpose-built device consisting of a perfo-
rated plastic bag attached to a mouthpiece (Easysampler,
Quintron Instrument Company, Milwaukee, WI) where
vacuum tubes were inserted to collect a sample of the
expired breath [27,28]. Breath sample collection takes
less than 30 sec. Our preliminary data showed that to
effectively follow
13C-DHA metabolism in the blood,
samples should be collected over a 4 wk period after
tracer intake, by which time remaining
13C-DHA in
plasma has essentially returned to baseline [29]. Enrich-
ment of
13C-DHA in plasma lipid classes was performed
by gas chromatography-combustion-isotope ratio mass
spectrometry as previously described [30]. The
13C/
12C
values of the samples and the reference were used to
calculate the δ per mil values which were designated
thereafter as atom percent excess (APE). Calculation of
13C in DHA, DPA, EPA and a-linolenic acid (ALA)
Table 1 Baseline characteristics (means ± SD) of the two
groups
Young
(n = 6)
Elderly
(n = 6)
p *
Age (years) 26.8 ± 2.6 76.5 ± 2.7 0.004
Male/Female 3/3 2/4 0.337
Weight (kg) 84.0 ± 20.1 64.9 ± 9.7 0.078
Body Mass Index (kg/m
2) 26.9 ± 5.9 24.9 ± 3.5 0.670
Plasma Triglycerides (mmol/L) 0.71 ± 0.18 0.94 ± 0.28 0.078
Plasma Total Cholesterol (mmol/L) 4.32 ± 0.58 5.26 ± 0.33 0.016
Plasma Fatty Acids
a(%)
Sum Saturates 32.7 ± 2.1 29.3 ± 2.7 0.055
Sum Monounsaturates 24.6 ±3.2 26.6 ± 2.7 0.200
Linoleate 32.5 ± 5.0 30.9 ± 1.9 0.630
Arachidonate 6.3 ± 0.4 8.3 ± 1.3 0.013
a-Linolenate < 0.1 0.5 ± 0.6 0.059
Eicosapentaenoate 0.6 ± 0.4 1.2 ± 0.3 0.012
Docosapentaenoate 0.1 ± 0.2 0.3 ± 0.3 0.211
Docosahexaenoate 1.7 ± 0.4 1.4 ± 0.8 0.872
aPlasma total lipids.
*Mann-Whitney test.
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[31]. Enrichment of
13C in breath CO2 following the
ingestion of the
13C tracer was analyzed by isotope ratio
mass spectrometry (Europa 20 - 20, Sercon Ltd, Crewe,
Cheshire, UK) as previously described [28]. 5% CO2/N2
was the reference gas and He was the carrier gas (Prax-
air Canada Inc. Mississauga, ON, Canada). Percent dose
recovered from b-oxidation of
13C-DHA in the breath
was calculated as described by Freemantle et al. [27].
Cumulative oxidation of
13C-DHA was determined by
calculating area under the curve between each time
points using GraphPad Prism 5 software (San Diego,
CA, USA) followed by summing the areas at each time.
Analytical methodology
Total lipids from 0.5 ml plasma were extracted into chloro-
form-methanol and a mixture of esterified (TG, CE or PL)
and non-esterified (FFA) heptadecanoate internal standard
was added for quantification. The lipid classes were sepa-
rated by thin layer chromatography using petroleum ether:
ethyl ether: methanol: acetic acid (85:15:1:2.5) as migration
solvent. At the end of the chromatographic runs, the plates
were sprayed with a solution of 2’,7’-dichlorofluorescein,
and viewed under UV light. Free fatty acids (FFA) and TG
were directly methylated with boron trifluoride in methanol
(14%). Cholesteryl esters (CE) were saponified to remove
cholesterol from the methyl esters mixture since cholesterol
can damage our GC column if injected with our methyl
esters. PL were saponified to assure full fatty acid recovery.
Fatty acid recovery from TG is less of a problem than for
PL so TG were directly transmethylated.
Data expression and statistics
Six participants in each group was required to have suffi-
cient power analysis with a b = 0.8 which is defined as
80% chance to reject the null hypothesis which state that
there is no relationship between the variable of interest.
Data are shown as means ± SEM, except as indicated.
Sample sizes of less than 12 values simply don’tp r o v i d e
enough data to discriminate between Gaussian and non-
Gaussian distributions. In this situation non-parametric
statistics are appropriate [32]. Fatty acid values and %
b-oxidation were compared between young and elderly at
each point using the non-parametric Mann-Whitney test
(SPSS; Chicago, Illinois, USA). Apparent retroconversion
of
13C-DHA was calculated by summing
13C-labelled
DPA, EPA and ALA measured in plasma total lipids. The
sum of
13C-labelled DPA, EPA and ALA was called
13C-omega-3 PUFA and was expressed as pmol/ml
plasma. Statistical significance was set at p ≤ 0.05.
Results
Mean age of the young and the elderly were 26.8 y and
76.5 y, respectively, so that there was a gap of 50 y
between the two groups (Table 1). Weight and body
mass index was not different between the two groups.
At baseline, the elderly had 22% higher plasma choles-
terol compared to the young. At baseline, the profile of
fatty acids in total lipids of fasting plasma was similar
between the young and the elderly with the exception of
arachidonic acid and EPA, which were 32% and 100%
higher in the elderly, respectively. At baseline, % DHA
was not different between the two groups (Table 1).
13C-DHA in plasma
Four h after giving the tracer,
13C-DHA peaked in
plasma total lipids of the elderly (Figure 1, upper panel)
at a level 3.5 times higher than in the young (p = 0.028).
Plasma
13C-DHA concentration decreased 24 h after
dosing, at which time it was no longer statistically differ-
ent in the two groups. Seven days later,
13C-DHA con-
centration was still declining in both groups but was
significantly higher in the elderly (p = 0.045). Twenty
eight days post-intake,
13C-DHA returned close to base-
line and was not different in the two groups (Figure 1A).
Four h post-dose,
13C-DHA was more than 4 fold
higher in TG and FFA of the elderly but, in both
groups, returned to near baseline after 24 h (Figure 2).
13C - D H Ap e a k e di np l a s m aP L2 4hp o s t - d o s eb u t2 8 d
later was still significantly higher in the elderly (p =
0.031; Figure 2). Seven days after dosing,
13C-DHA was
2.5 fold higher in CE of the elderly (p = 0.029) and
remained so after 28d (p = 0.015).
Apparent retroconversion (13C-omega-3 PUFA)
In both groups, the summed value for
13C-omega-3
PUFA other than DHA peaked 24 h after the dose of
13C-DHA and was 2.2 times higher in the elderly (p =
0.045; Figure 1, middle panel).
13C-omega-3 PUFA
remained 2.1 times higher in the elderly 7d later.
13C-
EPA contributed the most to the sum of
13C-omega-3
PUFA after 24 h (p = 0.045), whereas 7d later,
13C-EPA
and
13C-ALA jointly contributed the most (data not
shown). Percent apparent retroconversion expressed as a
ratio of
13C-omega-3 PUFA relative to
13C-DHA con-
centration in plasma total lipids was not significantly
different between the young and the elderly and reached
1.5 ± 1.1% and 2.0 ± 1.6%, respectively after 7d, and 2.5
± 2.7% and 4.3 ± 6.2% after 28d, respectively (Figure 1,
lower panel).
b-Oxidation
Carbon-13 values in breath samples at 28d were very
low and not available in 3 young participants and
5 elderly participants. Hence, % dose of
13C-CO2 and
cumulative b-oxidation of
13C-DHA was calculated over
the first 7d post-dose (Figure 3). As a % of the dose
given,
13C-DHA b-oxidation was 1.9 times higher at 4 h
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Figure 1
13C-docosahexaenoic acid (DHA; upper panel),
13C-omega-3 PUFA (
13C-alpha-linolenate +
13C-eicosapentaenoate +
13C-
docosapentaenoate; middle panel) concentrations and ratio given as a percentage of
13C-omega-3 PUFA/
13C-DHA (lower panel) in
plasma total lipids of young (full symbols) and elderly (open symbols) over 28d after giving the
13C-DHA. Data are shown for n = 5 for
the young and n = 6 for the elderly (*P < 0.05).
Plourde et al. Nutrition & Metabolism 2011, 8:5
http://www.nutritionandmetabolism.com/content/8/1/5
Page 4 of 9post-dose in the elderly (p = 0.004), but was not signifi-
cantly different between the young and the elderly at 24 h
or at 7d (Figure 3; upper panel). Cumulative b-oxidation
over 7d reached 35% and 38% in the elderly and the
young participants, respective l y( n o td i f f e r e n t ;F i g u r e3 ,
lower panel).
Discussion
The aim of this study was to evaluate whether plasma
incorporation, apparent retroconversion, or b-oxidation
of
13C-DHA differed in the healthy elderly compared to
healthy young adults. We observed that within the post-
prandial period (+ 4 h) the elderly had at least 4 fold
higher
13C-DHA in plasma TG and FFA, and 1.9 fold
higher b-oxidation to
13C-CO2.
13C-DHA was also 2.5
fold higher in plasma CE of the elderly after 7d, and its
apparent retroconversion was 2.2 fold higher in the
elderly 24 h after the oral dose. Hence, our results indi-
cate that there are significant differences in DHA meta-
bolism during healthy aging which compliment, extend
and possibly help explain previous reports showing
somewhat higher plasma DHA in the elderly [5-9].
The distribution of
13C-DHA we observed in plasma
lipid classes of our young study participants agrees with
previous published papers [24,25,31]. We speculate that
the higher early rise in
13C-DHA in plasma TG and
FFA in the elderly (Figure 2) may potentially be
explained by the elderly having both higher postprandial
production of very low density lipoproteins which are
rich in TG [33], as well as a higher post-prandial FFA
response [7]. However, one limitation is that postpran-
dial TG-rich lipoproteins were not measured in this
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13C-docosahexaenoic acid (DHA) concentration in plasma triglycerides, free fatty acids, phospholipids, and cholesteryl esters
in the young (full symbols) and the elderly (open symbols) followed over 28d (N = 6 for the young and the elderly except n = 4 for
the elderly at 7d and 28d (* P < 0.05).
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4-fold higher
13C-DHA in plasma CE in the elderly after
7d persisted out to 28d and may be due to different
lipoprotein metabolism in the elderly as suggested by
their (i) higher plasma total cholesterol (Table 1),
(ii) higher plasma residence time of low density lipopro-
tein [34], and/or (iii) lower turnover of low density
lipoprotein [33].
The appearance of
13C in other omega-3 PUFA
besides DHA (mostly in
13C-EPA) was about 2 times
higher in the elderly 24 h to 7d after tracer intake. This
measure of apparent retroconversion of
13C-DHA to
13C-EPA could occur by one cycle of b-oxidation and
chain shortening [35]. Subsequent chain lengthening of
13C-EPA could explain the appearance of
13C-DPA.
Alternatively, recycling of carbon from PUFA through
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Figure 3 b-oxidation of
13C-docosahexaenoic acid (
13C-DHA) shown as % dose recovered over time (upper panel) and as cumulative
b-oxidation over time (lower panel) in young (full symbols) and the elderly (open symbols) over 7d (n = 6 for the young and the
elderly except n = 4 for the elderly at 24 h; *P < 0.05).
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known phenomenon [35], and could potentially become
part of ALA because humans can make small amounts
of ALA from 16:3 n-3, or omega-3 PUFA longer than
ALA via conventional elongation [36].
The mean total
13C-EPA and
13C-DPA appearing in
plasma is well below 10% even at 28d post-dose, so this
amount of apparent retroconversion would seem unli-
kely to fully account for net > 5% rise in plasma phos-
pholipid EPA after DHA supplementation reported
elsewhere [37], unless the process were substantially up-
regulated using multigram DHA supplements. Raised
plasma EPA after a DHA supplement may also be due
to reduced EPA turnover by sparing mechanisms with
enhanced dietary DHA.
We show for the first time that
13C-CO2 from b-
oxidation of
13C-DHA peaked at 4 h post-intake and
was 1.9 fold higher in the elderly (Figure 3). These data
confirm a preliminary report [29] showing that humans
b-oxidize
13C-DHA much more slowly than
13C-ALA
[28]. The major regulatory mechanism for the control of
b-oxidation is the availability of substrate, mostly as
fatty acids in postprandial circulating TG and FFA [38].
The higher b-oxidation of
13C-DHA at 4 h post-dose in
our elderly participants is in line with their higher
13C-DHA in plasma TG and FFA 4 h post-dose (Figure
2). After 7d,
13C-CO2 was still above baseline in both
groups although plasma
13C-DHA concentration had
returned close to baseline in TG and FFA. Cumulative
b-oxidation of
13C-DHA was not different in the young
and the elderly and reached 35 - 38% after 7d, which is
about half that seen for the same dose of
13C-ALA over
t h es a m et i m ep e r i o d[ 2 8 ] .U n d e rt h ec o n d i t i o n so ft h i s
study, these results give a rough estimate of about 3 wk
to turnover DHA to expired CO2, or a DHA biological
half-life of about 10 d. However, overall b-oxidation was
not higher in the elderly even though the elderly did
have
13C-EPA derived from
13C-DHA. There is no
implicit reason why the age-related difference in recov-
ery of
13Ca s
13C-EPA should be directly related to net
loss of
13C-DHA to
13CO2; both processes involve a
complex interchange of carbon. Furthermore, we do not
yet know how the EPA and other omega-3 fatty acids
became labelled with
13C; if it was via ‘direct’ retrocon-
version, i.e. by chain shortening, there is no implicit rea-
son why this form of retroconversion should be coupled
to the b-oxidation of DHA; if it was via oxidation to
acetyl-CoA, perhaps one would expect a closer correla-
tion between b-oxidation of DHA and EPA labelling.
Analytically, we cannot yet distinguish between these
two possibilities. Incidentally, the elderly did have higher
b-oxidation, but only at the earliest time point (+ 4 h).
The possible relevance of aging-related changes in DHA
metabolism to risk of chronic diseases, particularly
cognitive decline, remains to be established. Fish intake
seems to decrease the risk of cognitive decline [2] and
EPA and DHA in blood are biomarkers of fish intake [4]
but, paradoxically, an overview of the literature shows that
lower blood DHA is not seen in Alzheimer’s disease or
other forms of dementia [2,39]. Indeed, the aging-asso-
ciated changes in DHA metabolism we report here suggest
that higher plasma DHA in the elderly could actually mask
lower DHA availability to the brain. Another factor that
was not considered in this small study is the presence of
apolipoprotein E ε4 gene polymorphisms which appear to
alter plasma EPA and DHA metabolism [40].
Because of the limited availability of the tracer and its
very high cost, we had only six participants per group.
However, a tracer is much more sensitive and specific
than a fish oil supplement such that low number of par-
ticipants per group can still generate useful and statisti-
cally valid results [23]. Indeed, previous studies using
13C-DHA used only 3 - 4 participants [24,25,29,31].
Conclusions
We conclude from this month long study that in the
healthy elderly, 50 mg of
13C-DHA is retained longer in
the blood and undergoes more b-oxidation and more
apparent retroconversion th a ni ny o u n ga d u l t s .G i v e n
the potential importance of DHA for cardiovascular and
brain health and the increasing elderly population, this
alteration in DHA metabolism in the elderly may have
some bearing on their vulnerability to cognitive decline.
Further studies with
13C-DHA should examine – (i)
mechanisms at the root of these aging-associated differ-
ences, (ii) whether there is a link to the cognitive health
of the elderly, and (iii) whether the dietary need for
DHA may be different in the elderly.
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